search
Back to results

Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial (ICH ADAPT)

Primary Purpose

Intracerebral Hemorrhage

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
labetalol/hydralazine/enalapril
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intracerebral Hemorrhage focused on measuring Stroke, Hypertension, Cerebral Blood Flow, CT Perfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥18 years
  • Acute primary ICH demonstrated with CT scan
  • Onset ≤ 24 h prior to randomization

Exclusion Criteria:

  • Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic valvular heart disease
  • Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic dissection
  • Definite evidence that the ICH is secondary to underlying cerebral or vascular pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic transformation of an ischemic infarct
  • Previous ischemic stroke within 30 days of current event NB: Prior ICH is not an exclusion criterion
  • Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an exclusion criterion
  • Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or Creatinine >160 μmol/l)

Sites / Locations

  • University of Calgary
  • University of Alberta
  • Grey Nuns Hospital
  • University of Ottawa

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Target systolic BP < 150 mmHg

Target systolic BP < 180 mmHg

Arm Description

Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.

Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.

Outcomes

Primary Outcome Measures

The primary outcome is cerebral blood flow in the perihematoma region, measured with CT perfusion, 2 hours after randomization.

Secondary Outcome Measures

Hematoma expansion rates at 24 hours.

Full Information

First Posted
August 21, 2009
Last Updated
February 24, 2012
Sponsor
University of Alberta
Collaborators
Heart and Stroke Foundation of Canada, Alberta Heritage Foundation for Medical Research
search

1. Study Identification

Unique Protocol Identification Number
NCT00963976
Brief Title
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial
Acronym
ICH ADAPT
Official Title
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alberta
Collaborators
Heart and Stroke Foundation of Canada, Alberta Heritage Foundation for Medical Research

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Management of blood pressure (BP) in the acute phase of intracerebral hemorrhage (ICH) remains controversial. Although it has been established that there is a transient moderate reduction of perihematoma cerebral blood flow (CBF) in acute ICH, the effect of BP treatment is unknown. The potential for exacerbation of CBF has precluded routine aggressive BP reduction. Aim and Hypothesis: The primary study aim is to demonstrate the feasibility and safety of acute BP reduction to < 150 mmHg systolic using a standardized protocol in ICH patients. It is hypothesized that CTP will not demonstrate evidence of perihematoma ischemia following acute BP reduction. Design: ICH ADAPT is a randomized blinded endpoint trial. Acutely hypertensive ICH patients are randomized to a target systolic BP of < 150 mmHg or < 180 mmHg. Patients are treated with intravenous (IV) labetalol/hydralazine/enalapril. Study Outcomes: The primary outcome is cerebral blood flow in the perihematoma region, measured with CT perfusion, 2 hours after randomization. Secondary outcomes include the difference in BP at 1 and 2 hours post-randomization in the two treatment groups and hematoma expansion rates at 24 hours. Discussion: ICH ADAPT is the only randomized trial designed specifically to identify any hemodynamic changes in the perihematoma region secondary to aggressive BP management. The results of this trial will facilitate ongoing and future studies aimed at determining the efficacy of rapid BP reduction in acute ICH.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracerebral Hemorrhage
Keywords
Stroke, Hypertension, Cerebral Blood Flow, CT Perfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
74 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Target systolic BP < 150 mmHg
Arm Type
Experimental
Arm Description
Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
Arm Title
Target systolic BP < 180 mmHg
Arm Type
Active Comparator
Arm Description
Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
Intervention Type
Drug
Intervention Name(s)
labetalol/hydralazine/enalapril
Intervention Description
Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Primary Outcome Measure Information:
Title
The primary outcome is cerebral blood flow in the perihematoma region, measured with CT perfusion, 2 hours after randomization.
Time Frame
2 hours post randomization
Secondary Outcome Measure Information:
Title
Hematoma expansion rates at 24 hours.
Time Frame
24 hours post randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years Acute primary ICH demonstrated with CT scan Onset ≤ 24 h prior to randomization Exclusion Criteria: Contraindication to BP reduction i.e., severe arterial stenosis or high-grade stenotic valvular heart disease Indication for urgent BP reduction i.e., hypertensive encephalopathy, or aortic dissection Definite evidence that the ICH is secondary to underlying cerebral or vascular pathology, i.e., AVM, aneurysm, tumour, trauma, vasculitis, or hemorrhagic transformation of an ischemic infarct Previous ischemic stroke within 30 days of current event NB: Prior ICH is not an exclusion criterion Planned surgical resection of hematoma NB: Extraventricular Drain placement is not an exclusion criterion Contraindication to CT perfusion imaging (i.e. contrast allergy, metformin use or Creatinine >160 μmol/l)
Facility Information:
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2B7
Country
Canada
Facility Name
Grey Nuns Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6L 5X8
Country
Canada
Facility Name
University of Ottawa
City
Ottawa
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
31131671
Citation
Klahr AC, Kosior JC, Dowlatshahi D, Buck BH, Beaulieu C, Gioia LC, Kalashyan H, Wilman AH, Jeerakathil T, Emery DJ, Shuaib A, Butcher KS. Lower Blood Pressure Is Not Associated With Decreased Arterial Spin Labeling Estimates of Perfusion in Intracerebral Hemorrhage. J Am Heart Assoc. 2019 Jun 4;8(11):e010904. doi: 10.1161/JAHA.118.010904.
Results Reference
derived
PubMed Identifier
25700288
Citation
McCourt R, Gould B, Kate M, Asdaghi N, Kosior JC, Coutts S, Hill MD, Demchuk A, Jeerakathil T, Emery D, Butcher KS. Blood-brain barrier compromise does not predict perihematoma edema growth in intracerebral hemorrhage. Stroke. 2015 Apr;46(4):954-60. doi: 10.1161/STROKEAHA.114.007544. Epub 2015 Feb 19.
Results Reference
derived
PubMed Identifier
25147326
Citation
Gould B, McCourt R, Gioia LC, Kate M, Hill MD, Asdaghi N, Dowlatshahi D, Jeerakathil T, Coutts SB, Demchuk AM, Emery D, Shuaib A, Butcher K; ICH ADAPT Investigators. Acute blood pressure reduction in patients with intracerebral hemorrhage does not result in borderzone region hypoperfusion. Stroke. 2014 Oct;45(10):2894-9. doi: 10.1161/STROKEAHA.114.005614. Epub 2014 Aug 21.
Results Reference
derived
PubMed Identifier
24692481
Citation
McCourt R, Gould B, Gioia L, Kate M, Coutts SB, Dowlatshahi D, Asdaghi N, Jeerakathil T, Hill MD, Demchuk AM, Buck B, Emery D, Butcher K; ICH ADAPT Investigators. Cerebral perfusion and blood pressure do not affect perihematoma edema growth in acute intracerebral hemorrhage. Stroke. 2014 May;45(5):1292-8. doi: 10.1161/STROKEAHA.113.003194. Epub 2014 Apr 1.
Results Reference
derived
PubMed Identifier
23391776
Citation
Butcher KS, Jeerakathil T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB, Gould B, McCourt R, Asdaghi N, Findlay JM, Emery D, Shuaib A; ICH ADAPT Investigators. The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial. Stroke. 2013 Mar;44(3):620-6. doi: 10.1161/STROKEAHA.111.000188. Epub 2013 Feb 7.
Results Reference
derived
PubMed Identifier
20536619
Citation
Butcher K, Jeerakathil T, Emery D, Dowlatshahi D, Hill MD, Sharma M, Buck B, Findlay M, Lee TY, Demchuk AM. The Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial: ICH ADAPT. Int J Stroke. 2010 Jun;5(3):227-33. doi: 10.1111/j.1747-4949.2010.00431.x.
Results Reference
derived

Learn more about this trial

Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial

We'll reach out to this number within 24 hrs